论文部分内容阅读
目的观察甘精胰岛素联合口服降糖药物治疗2型糖尿病的临床疗效和安全性。方法选择口服降糖药物血糖控制不佳的56例老年2型糖尿病患者,随机分为加用甘精胰岛素治疗组和低精蛋白锌胰岛素组两组,观察治疗前和治疗24周后各组的FBG、P2hBG、HbA1c和BMI的变化。同时对两种方案的安全性进行比较。结果治疗24周后甘精胰岛素组与低精蛋白锌胰岛素组均能降低FBG、P2hBG、HbA1c,且疗效相当,组内治疗前后比较差异无统计学意义,而BMI均没有明显变化。但甘精胰岛素组的严重低血糖发生率明显低于低精蛋白锌胰岛素组。结论甘精胰岛素组与低精蛋白锌胰岛素组在降低血糖方面的疗效相当,但甘精胰岛素组比低精蛋白锌胰岛素组治疗安全性高。
Objective To observe the clinical efficacy and safety of insulin glargine combined with oral hypoglycemic agents in the treatment of type 2 diabetes. Methods Fifty-six elderly patients with type 2 diabetes with poor glycemic control by oral hypoglycemic drugs were randomly divided into two groups: plus insulin glargine group and hypoproteinemia insulin group. The levels of FBG, P2hBG, HbA1c and BMI changes. At the same time the safety of the two programs are compared. Results After treatment for 24 weeks, FBG, P2hBG and HbA1c were lower in both glargine and hypophrenaline insulin groups, and the effect was similar. There was no significant difference between before and after treatment in the group, but no significant change in BMI. However, the incidence of severe hypoglycaemia in the insulin glargine group was significantly lower than that in the hypoproteinemia zinc insulin group. Conclusion The insulin glargine group and the hypophoproteine sodium insulin group have the same effect in lowering blood sugar, but the insulin glargine group is more safe than the hypophosphamide insulin group.